Dr. Choi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
119 Belmont St
Worcester, MA 01605Phone+1 508-334-2846Fax+1 508-856-3981
Education & Training
Dana-Farber Cancer InstitutePost-Doctoral Fellowship, 2003 - 2008
Massachusetts General HospitalFellowship, Gastroenterology, 2000 - 2005
University of California (San Francisco)Residency, Internal Medicine, 1997 - 2000
Weill Cornell MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1999 - Present
MA State Medical License 2003 - 2026
NH State Medical License 2024 - 2026
ME State Medical License 2010 - 2025- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 93 citationsUpdate on non-canonical microRNAs.Ahmed Maher Abdelfattah, Chanhyun Park, Michael Y. Choi
Biomolecular Concepts. 2014-08-01 - 28 citationsA role for intestinal alkaline phosphatase in preventing liver fibrosis.Yang Liu, Paul M Cavallaro, Byeong-Moo Kim, Tao Liu, Hongyan Wang
Theranostics. 2021-01-01 - 41 citationsIntestinal Alkaline Phosphatase Attenuates Alcohol-Induced Hepatosteatosis in Mice.Sulaiman R. Hamarneh, Byeong-Moo Kim, Kanakaraju Kaliannan, Sara A. Morrison, Tyler J. Tantillo
Digestive Diseases and Sciences. 2017-04-19
Lectures
- Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase Ib/II Study of Ibrutinib in Combination with Obinutuzumab-Gazyva As First-Line Treatment for Patients with Chronic Lymphocytic Leukemia > 65 Years Old or with ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Enzyme Treatment Reduces Alcohol-Induced Liver Damage in Mouse ModelsApril 25th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
